Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin® SDH in previously treated patients with severe haemophilia A

Haemophilia

Volumn 10, Issue 5, 2004, Pages 438-448

  Wolf, Daniele M ^a   Rokicka Milewska, R ^b   Lopaciuk, S ^b   Skotnicki, A B ^d   Klukowska, A ^b   Laguna, P ^b   Windyga, J ^c   Kotitschke, R ^a   Struff, W G ^a  

^a BIOTEST AG   (Germany)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^d JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Factor VIII inhibitor; Haemophilia A; Half life; Incremental recovery; Pharmacokinetics

Indexed keywords

BILIRUBIN; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; HAEMOCTIN SDH;

ACCURACY; ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HEADACHE; HEMOPHILIA A; HEMOSTASIS; HUMAN; HYPERBILIRUBINEMIA; IMMUNOCOMPETENCE; IMMUNOGENICITY; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; ORTHOPEDIC SURGERY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; SCHOOL CHILD; SURGICAL TECHNIQUE; THROMBOCYTOPENIA; WOUND HEALING;

ADOLESCENT; ANTIBODIES; CHILD; FACTOR VIII; HALF-LIFE; HEMOPHILIA A; HEMOSTASIS; HUMANS; MALE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 4844222953     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2004.00947.x     Document Type: Article

References (17)

1. The European Agency for the Evaluation of Medicinal Products (EMEA). Note for guidance on the clinical investigation of human plasma derived factor VIII and IX products. CPMP/BPWG/198/95 rev. 1, October 19th, 2000, coming into operation April, 2001.
2. Horowitz B, Wiebe ME, Lippin A, Stryker MH. Inactivation of viruses in labile blood derivates. I. Disruption of lipid-enveloped viruses by tri (n-butyl) phosphate detergent combinations. Transfusion 1985; 25: 516-22.
3. The European Evaluation Agency for Medicinal Products. Core SPC for human plasma derived and recombinant coagulation factorVIII products. CPMP/BPWG/1619/99, June 29th, 2000, coming into operation December, 2000.
4. Kasper CK, Aledort LM, Counts RB et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 869-72.
5. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
6. Biggs R. Human Blood Coagulation, Haemostasis and Thrombosis. Blackwell Scientific Publications 1976; 708-10.
7. Berntorp E, Björkman S. The pharmacokinetics of clotting factor therapy. Haemophilia 2003; 9: 353-59.
8. Björkman S, Carlsson M. The pharmacokinetics of factor VIII and factor IX: methodology, pitfalls and applications. Haemophilia 1997; 3: 1-8.
9. Björkman S, Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet 2001; 40: 815-32.
10. Schwaab R, Brackmann HH, Meyer C et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74: 1402-6.
11. Oldenburg J, El-Maarri O, Schwaab R. Inhibitor development in correlation to factor VIII genotypes. Haemophilia 2002; 8 (Suppl. 2): 23-9.
12. Ehrenforth S, Kreuz W, Scharrer I et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
13. Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients - a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999; 5: 145-54.
14. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35.
15. Peerlinck K, Arnout J, Gilles JG, Saint-Remy JM; Vermylen J. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemost 1993; 69: 115-8.
16. Peerlinck K, Arnout J, Di Giambattista M, Gilles JG, Laub R, Jacquemin M et al. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor concentrate. Thromb Haemost 1997; 77: 80-6.
17. Mauser-Bunschoten EP, Rosendaal FR, Nieuwenhuis HK, Roosendaal G, Briet E, van den Berg HM. Clinical course of factor VIII inhibitors developed after exposure to a pasteurised Dutch concentrate compared to classic inhibitors in hemophilia A. Thromb Haemost 1994; 71: 703-6.